Anebulo Pharmaceuticals Inc (ANEB) - Total Assets
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) holds total assets worth $9.42 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anebulo Pharmaceuticals Inc - Total Assets Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Anebulo Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Anebulo Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Anebulo Pharmaceuticals Inc's total assets of $9.42 Million consist of 98.5% current assets and 1.5% non-current assets. Review ANEB current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.7% |
| Accounts Receivable | $73.22K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Anebulo Pharmaceuticals Inc (ANEB) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anebulo Pharmaceuticals Inc's current assets represent 98.5% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 95.7% of total assets in 2025, down from 99.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Anebulo Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Anebulo Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Anebulo Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.71 | 17.52 | 13.30 |
| Quick Ratio | 16.71 | 17.52 | 13.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.72 Million | $14.52 Million | $3.61 Million |
Anebulo Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Anebulo Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 1.11 |
| Asset Growth Rate (YoY) | 198.2% |
| Total Assets | $12.15 Million |
| Market Capitalization | $13.52 Million USD |
Valuation Analysis
Above Book Valuation: The market values Anebulo Pharmaceuticals Inc's assets above their book value (1.11x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Anebulo Pharmaceuticals Inc's assets grew by 198.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual total assets of Anebulo Pharmaceuticals Inc from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $12.15 Million | +198.19% |
| 2024-06-30 | $4.07 Million | -65.10% |
| 2023-06-30 | $11.67 Million | -25.09% |
| 2022-06-30 | $15.58 Million | -28.05% |
| 2021-06-30 | $21.65 Million | +615.00% |
| 2020-06-30 | $3.03 Million | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more